A Terapia Hormonal da Menopausa como estratégia de prevenção da Síndrome Metabólica em mulheres na pós-menopausa
DOI:
https://doi.org/10.36557/2674-9432.2026v5n1p789-813Keywords:
menopausa, síndrome metabólica, estradiol, terapia hormonal, PrevençãoAbstract
Objective: To evaluate whether menopausal hormone therapy (MHT) can serve as a preventive strategy against metabolic syndrome (MetS) in postmenopausal women, based on the most recent scientific evidence. Methods: This integrative literature review was conducted between February and April 2025, utilizing the PubMed, SciELO, and LILACS databases. The descriptors "menopausal hormone therapy," "estradiol," "estrogen," and "metabolic syndrome" were used, combined with Boolean operators. Inclusion criteria included full-text articles published within the last five years. Exclusion criteria comprised articles unrelated to the topic, duplicates, or non-scientific works. A total of nine articles were analyzed in full. Discussion: The studies indicate that the use of estradiol, either alone or in combination with progestogens such as drospirenone, provides significant metabolic benefits, including reduced insulin resistance, decreased visceral adiposity, and improved lipid profiles. These positive effects are more evident when MHT is initiated before the age of 60 and/or within 10 years of menopause, corroborating the "window of opportunity" hypothesis. Conclusion: When prescribed early and on an individualized basis, MHT may play a protective role against MetS. However, its indication must take into account cardiovascular risk and individual contraindications.
Downloads
References
AZIZIAN, H. et al. Progesterone eliminates 17β-estradiol-Mediated cardioprotection against diabetic cardiovascular dysfunction in ovariectomized rats. Biomedical journal (Mumbai.Print), v. 44, n. 4, p. 461–470, 1 ago. 2021.
DEADMOND, A.; KOCH, C. A.; PARRY, J. P. Ovarian Reserve Testing. Endotext, Spring 2022.
DONNINO, A. et al. Efectos de la terapia hormonal con drospirenona / 17 β - estradiol sobre los parámetros del síndrome metabólico en posmenopáusicas. Revista Digital de Postgrado, v. 9, n. 2, p. e227–e227, 2020.
I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arquivos Brasileiros de Cardiologia, v. 84, p. 3–28, abr. 2005.
JEONG, H. G.; PARK, H. Metabolic Disorders in Menopause. Metabolites, v. 12, n. 10, p. 954, 8 out. 2022.
KHATER, S. I. et al. Autophagy characteristics of phytoestrogens in management and prevention of diseases: A narrative review of in-vivo and in-vitro studies. Journal of Advanced Veterinary and Animal Research, v. 10, n. 2, p. 308–308, 1 jan. 2023.
LEE, H. J. et al. Timing of hormone therapy and its association with cardiovascular risk and metabolic parameters in 4-vinylcyclohexene diepoxide-induced primary ovarian insufficiency mouse model. Gynecological Endocrinology, v. 39, n. 1, 21 ago. 2023.
LIU, S. et al. The impact of sex hormones on metabolic syndrome: univariable and multivariable Mendelian randomization studies. Diabetology & Metabolic Syndrome, v. 16, n. 1, 3 set. 2024.
LIU, X. et al. Conversion of estriol to estrone: A bacterial strategy for the catabolism of estriol. Ecotoxicology and Environmental Safety, v. 280, p. 116564, 11 jun. 2024.
LOBO, R. A.; GOMPEL, A. Management of menopause: a view towards prevention. The Lancet Diabetes & Endocrinology, v. 10, n. 6, p. 457–470, jun. 2022.
MEDORO, A. et al. Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives. Nutrients, v. 16, n. 24, p. 4313, 13 dez. 2024.
MARLATT, K. L. et al. Body composition and cardiometabolic health across the menopause transition. Obesity, v. 30, n. 1, p. 14–27, 21 dez. 2021.
MOTLANI, V. et al. Changed Endocrinology in Postmenopausal Women: A Comprehensive View. Cureus, v. 15, n. 12, 29 dez. 2023.
OLIVEIRA, M. et al. Diretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024. Arquivos Brasileiros de Cardiologia, v. 121, n. 7, 1 jan. 2024.
OPOKU, A. A.; ABUSHAMA, M.; KONJE, J. C. Obesity and Menopause. Best Practice & Research Clinical Obstetrics & Gynaecology, v. 88, p. 102348–102348, 1 jun. 2023.
PARKIN, R. A.; MURRAY, A. J. The therapeutic potential of irisin to mitigate the risk of metabolic syndrome in postmenopausal women. Frontiers in reproductive health, v. 6, 8 jul. 2024.
PASCHOU, S. A.; ATHANASIADOU, K. I.; NIKOLAOS PAPANAS. Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review. Diabetes Therapy, v. 15, n. 4, p. 741–748, 16 fev. 2024.
PROSSNITZ, E. R.; BARTON, M. The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nature Reviews Endocrinology, 16 mai. 2023.
RODRIGUEZ, C. P.; MICHOS, E. D. Menopause and diabetes: Interconnected associations of risk. Endocrine Research, p. 1–11, 21 abr. 2025.
TALARICO, C. H. Z. et al. Progesterone Has No Impact on the Beneficial Effects of Estradiol Treatment in High-Fat-Fed Ovariectomized Mice. Current Issues in Molecular Biology, v. 45, n. 5, p. 3965–3976, 3 mai. 2023.
TALAULIKAR, V. Menopause transition: Physiology and Symptoms. Best Practice & Research Clinical Obstetrics & Gynaecology, v. 81, p. 3–7, mar. 2022.
XIAO, Z.; LIU, H. The estrogen receptor and metabolism. Women’s health, v. 20, 1 jan. 2024.
YU, K. et al. Estrogen Receptor Function: Impact on the Human Endometrium. Frontiers in Endocrinology, v. 13, 28 fev. 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lays Maria Alves Dias Pinheiro, Taciana Assis Bezerra Negri, Alexandre Jorge de Andrade Negri Junior, Gregorio Fernandes Gonçalves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Você tem o direito de:
- Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
- Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
- O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.
De acordo com os termos seguintes:
- Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
